Podcast Index
Explora podcasts por categoría, abre episodios recientes y descarga audio para escucharlo sin conexión.
BioCentury This Week
BioCentury
AI News Today | Julian Goldie Podcast
Julian Goldie
Die Potenzialwerkstatt
Andreas Nemeth - Der Potenzialentwickler
NomadTreneur
AC Wilson
Alles auf Aktien – Die täglichen Finanzen-News
WELT
Den nya ekonomin
Dagens industri
Conversions und Copywriting Podcast
Tim Gelhausen
Likes, Leads... Umsatz! Planbar mehr Kunden mit Social Media, KI und Meta Ads
Björn Tantau | Planbar mehr Kunden mit Social Media, KI und Meta Ads
Morgenkaffen med Finansavisen
Finansavisen
Richissime
Delphine Pinon
Becker’s Healthcare Podcast
Becker's Healthcare
YIELD Today With Dallin Candland
Dallin
The Green Room: Questions That Matter Most In Business
Deloitte UK
How HR Leaders Change the World
Cecilia Crossley
JFDI — The Show for Freelance Social Media Managers
The Two Lauras
Was Bitcoin bringt - mit Niko Jilch
Binifico
The Family in Business Podcast
Metropole Mastermind
DIETHELM & GENNER
Cornelia Diethelm & Sarah Genner
The Science of Fitness Podcast
Science of Fitness
Unfrazzle
Louise Miller
The Immortal Life of Agencies
Co:definery
CHEFGESPRÄCHE
Daniel Kubitza
Ranní brífink
Hospodářské noviny
Hidden Mentality
Rishi Kurada
Erichsen Geld & Gold, der Podcast für die erfolgreiche Geldanlage
Lars Erichsen
Audio-CD.at Indie Podcasts: Wiener Börse, Sport, Musik (und mehr)
Christian Drastil Comm. (Agentur für Investor Relations und Podcasts)
Jugeote: Finances personnelles, Investissement, Epargne, Argent, patrimoine immobilier, ETF, Bourse
Finances personnelles • Investissement • Epargne • Argent • Immobilier • Bourse
Leman Tech Leadership Podcast
Aleksandra Lemańska
Theo - t3․gg
Theo - t3․gg
Thinking Crypto News & Interviews
Tony Edward
36氪·商业情报局（第二季）
36氪音频
The Call from ausbiz
ausbiz
The Jamie Kern Lima Show
Jamie Kern Lima
BWP - Le podcast de Business Women in Paris
Business Women in Paris
Frisch an die Arbeit
DIE ZEIT
Handelsblatt Morning Briefing - News aus Wirtschaft, Politik und Finanzen
Friederike Hofmann, Sven Prange und die Handelsblatt Redaktion, Handelsblatt
Better: The Brand Designer Podcast
Jen Davis
Negocios
BioCentury
New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts re...
AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the takeo...
Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for fresh biotech paper on NASDAQ, including the $...
Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too.From AI to NAMs to starting a Phase I trial in the U.S., BioCentury’s 3rd Grand Round...
FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdi...
Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data...
At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field’s approach to t...
Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin disc...
China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s analysts, along with special guests Detlev Mennerich, head of Boehringer I...
Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commissioner shifting the question from whether he will be fired to when. On the lates...
UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therapeutics, one of the leading T cell engager companies. On the latest BioCe...
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make ...
Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting in San Diego as biotechs unveiled their latest preclinical and first-i...
The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon become the largest biotech IPO ever on NASD...
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Australia, China and the U.K. On the latest BioCentury This Week podcast, ...
Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but will the Mideast conflict halt biotech’s recovery? On the latest BioCentur...
Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed to de-risk assets. The new momentum from Asia, in particular China, has added a f...
A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podcast, BioCentury’s Paul Bonanos assesses last week’s deals by Merck, which is lay...
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how the company has built...
Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to debut on NASDAQ — but will geopolitical tensions and war in the Middle East scut...
Completa el formulario de abajo. Asegúrate de seleccionar tanto País como Géneros.
Envíanos un mensaje abajo. Te responderemos en un plazo de 24 horas.